Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. ÌýYou can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
WELCOME BACK
or
Phase 1 study of CB-839, a first-in-class oral inhibitor of glutaminase, in combination with paclitaxel in patients with advanced triple negative breast cancer
ÌÇÐÄ´«Ã½
Phase 1 study of CB-839, a first-in-class oral inhibitor of glutaminase, in combination with paclitaxel in patients with advanced triple negative breast cancer Kalinsky, K., Harding, J. J., DeMichele, A., Infante, J. R., Gogineni, K., Owonikoko, T. K., Isakoff, S., Iliopoulos, O., Patel, M. R., Munster, P., Telli, M. L., Jenkins, Y., Fiji, G. P., Whiting, S. H., Meric-Bernstam, F. AMER ASSOC CANCER RESEARCH. 2018View details for